Cyrus Biotechnology
Cyrus Biotechnology develops computationally engineered biologics from natural proteins for therapeutic applications, with lead programs targeting severe autoimmune diseases and acute respiratory distress syndrome. The company uses protein design algorithms and laboratory methods to create novel variants and fusion proteins, aiming to provide superior efficacy and address unmet medical needs.
Facts
- HQ
- Seattle, Washington, US
- Sectors
- Biotechnology Research
- Founded
- 2014
- Type
- Corporation Seattle business license
- Employees
- 17
- Registered name
- Cyrus Biotechnology Inc Seattle business license
- Stage
- Series B
- Members see funding amounts. .
- Founders
- David Baker
Is this your organization? Claim it
Early Pre-seed Angel Investing DD in Medical bioscience startups
Some of the companies are medical companies where people are having a questions about how you might evaluate a medical company. We have invited Eric Larsen to talk about his approach to evaluating a medical company. Eric Larsen serves as Board Chairman, Innovative Fund Administrator & Life Science Committee Chair at Alliance of Angels. He also serves as Board Observer at Cyrus Biotechnology. He is also a Founding Investor at Pack Ventures. He was a Co-Founder and served as Chief Executive Officer & Chairman at SiDx.
People
-
Lucas Nivon Executive Officer, Director, Co-Founder and Chief Executive Officer
-
Yifan Song Director, Co-founder and Chief Technology Officer
-
Erik Procko Executive, Chief Scientific Officer